Search clinical trials for: no germline BRCA mutation

Total 262339 results

University of Kansas Medical Center
Tesaro, Inc.

Active, not recruiting

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial (NIRA-PANC)

Pancreatic Cancer

United States
Chang Gung Memorial Hospital
Intuitive Surgical

Active, not recruiting

Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Nipple-sparing Mastectomy | Prophylactic Mastectomy

Taiwan
Revolution Medicines, Inc.
Sanofi; Amgen

Active, not recruiting

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
Weill Medical College of Cornell University

Completed

Web-based Family History Tool (Progeny)

Breast Cancer | Gynecologic Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Translational Research Center for Medical Innovation...
Japanese Gynecologic Oncology Group (JGOG); Department of Obstetrics and Gynecology... and other collaborators

Completed

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
Indiana University
Breast Cancer Research Foundation

Withdrawn

Breast Cancer BRCA1 Carriers: a Pilot Study

High-grade Serous Ovarian Cancer | BRCA1 Mutation | TNBC - Triple-Negative Breast Cancer

United States
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Dana-Farber Cancer Institute

Completed

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Advanced Cancers

United States
Hellenic Cooperative Oncology Group
NIPD Genetics

Completed

Tumor Molecular Profiling in Patients With Prostate Cancer

Prostate Cancer | Metastatic Prostate Adenocarcinoma

Greece
National Cancer Institute (NCI)

Terminated

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
AstraZeneca

Completed

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

BRCA or HRR+ Mutated Ovarian Cancer Patients

Italy, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
BeiGene

Completed

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

HER2-negative Breast Cancer

China
Medical University of Vienna

Completed

Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma (LUSTIC)

Carcinoma in Situ | Ovarian Cancer | Ovarian Epithelial Cancer

Austria, Belgium, Czechia, Denmark, Germany, Ireland, Netherlands, United Kingdom
Paul Speiser, Prof.MD,

Completed

Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing (EHUD)

Carcinoma in Situ | Ovarian Cancer | Ovarian Epithelial Cancer

Austria, Czechia, Germany, Ireland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Spanish Lung Cancer Group

Completed

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma (SLAT)

Non-small Cell Lung Cancer

Spain
AbbVie

No longer available

Expanded Access to Veliparib

High Grade Serous Ovarian Cancer | Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound | Triple Negative Breast Cancer (TNBC) | Patients Requiring Veliparib Suspension Formulation
European Institute of Oncology

Completed

Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing (BRCA-MEN)

BRCA1 Mutation | BRCA2 Mutation | Psychosocial Factors

Italy
AstraZeneca

Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Canada
Institut de Cancérologie de Lorraine

Completed

Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer (BOVARY Pilot)

Ovarian Cancer

France
Lei Li

Completed

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | Chinese | Homologous Recombination Genes

China
University of Texas Southwestern Medical Center

Completed

Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM) (SPrNSM)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Karolinska Institutet

Completed

BRCA1/2 and Effect of Mifepristone on the Breast

Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2

Sweden
AstraZeneca

Completed

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting (ZENSHIN)

Prostatic Neoplasms

Japan
AstraZeneca

Completed

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients (CHRISTELLE)

Ovarian Neoplasms

Japan
AbbVie

Completed

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Hungary, Israel, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Sweden, Ukraine
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Istituto Oncologico di Bari

Completed

Dietary Intervention and BRCA Penetrance

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Dietary Modification

Italy
Second Affiliated Hospital, School of Medicine,...

Completed

Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria

Lynch Syndrome

China
Australia New Zealand Gynaecological Oncology Group
BeiGene

Withdrawn

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)

Ovarian Cancer | Carcinosarcoma
Massachusetts General Hospital

Completed

Depression and Body Image Distress Following Mastectomy With Reconstruction

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
University of Washington
AbbVie

No longer available

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Triple-Negative Breast Cancer | Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada
Johns Hopkins University
National Cancer Institute (NCI); Lustgarten Foundation

Completed

Cancer of the Pancreas Screening Study (CAPS 3) (CAPS 3)

Pancreatic Neoplasm | Peutz-Jeghers Syndrome

United States
Pfizer

Terminated

Treatment Resistance Following Anti-cancer Therapies

Disease Progression

United States, Belgium, France, Argentina, United Kingdom
Columbia University
American Cancer Society, Inc.

Completed

Decision Support for BRCA Testing in Ethnically Diverse Women

Breast Cancer | Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation

United States
National Cancer Institute (NCI)

Completed

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Advanced Breast Cancer | Advanced Solid Tumors | Primary Peritoneal Cancer | Advanced Ovarian Cancer

United States
Samsung Medical Center

Completed

Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B)

Small Cell Lung Cancer

Korea, Republic of
Hellenic Cooperative Oncology Group

Completed

Germline Mutations in Pancreatic Adenocarcinoma (PaMPA)

Pancreatic Cancer | Hereditary Cancer | Predisposition, Genetic | Germline Mutation Abnormality

Greece
Fox Chase Cancer Center
National Cancer Institute (NCI)

Terminated

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Breast Cancer | BRCA1 Mutation

United States, Austria
National Cancer Institute (NCI)

Completed

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Li-Fraumeni Syndrome

United States
Lei Li

Unknown

A Training Set for the HRD Model in EOC

Epithelial Ovarian Cancer | Homologous Recombination Deficiency | Prognosis | BRCA Mutation | Loss of Heterozygosity | Platinum Resistance

China
Seoul National University Hospital
Bayer; Korean Society of Breast Imaging & Korean Society For Breast Screening

Unknown

Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Recurrent Breast Cancer | Metachronous Neoplasm

Korea, Republic of
Impact Therapeutics, Inc.

Unknown

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (SABRINA)

Ovarian Cancer

China
Rabin Medical Center

Completed

A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers

BRCA1 Gene Mutation | BRCA2 Gene Mutation

Israel
Xiaoxiang Chen

Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Adnexal Diseases | Gonadal Disorders | Endocrine Gland Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms and other conditions

China

Search clinical trials for: no germline BRCA mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations